TRIB's needle-free CGM+ sensor shows accurate 15-day results with no calibration, slashing costs and boosting access.

An update from Trinity Biotech ( ($TRIB) ) is now available. On August 12, 2025, Trinity Biotech announced breakthrough clinical trial results for ...

The company said its CGM+ system can deliver accurate readings across a 15-day lifespan, while also employing fewer ...

Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable ...

Trinity Biotech (Nasdaq:TRIB) today announced positive clinical trial results for its next-generation continuous glucose ...

Investing.com -- Trinity Biotech plc (NASDAQ: TRIB) stock rose 4.4% following the company’s announcement of positive clinical trial results for its next-generation continuous glucose monitoring (CGM) ...

Trinity Biotech (TRIB) announced clinical trial results demonstrating a major technical breakthrough and de-risking the commercial pathway for its ...

Clinical data confirms elimination of requirement for finger-stick calibration, de-risking pathway to commercialization for ...

Trinity Biotech plc recently unveiled CGM+, an AI-native, wearable biosensor that goes beyond traditional continuous glucose monitors and tracks glucose levels, cardiovascular activity and body ...

Trinity CineAsia has acquired European rights to $80M war epic Dongji Rescue (aka Dong Ji Island), inspired by the real story of the rescue by Chinese fisherman of British POWs from a WWII ...

Krystal Biotech's gene therapy Vyjuvek gains approval in Japan for treating dystrophic epidermolysis bullosa, expanding its global reach.

Detailed price information for Trinity Bio ADR (TRIB-Q) from The Globe and Mail including charting and trades.